Discover
LXEO
Lexeo Therapeutics, Inc.
4.45
2 x 3.39
2 x 5.59
bid
ask
-
0.21
4.40%
2 @ 04:00 PM
4.49 +0.04 (0.90%)
| Ytd | -55.19% | |
| 1y | 5.45% |
4.33
day range
4.79
3.60
52 week range
10.99
| Open | 4.67 | Prev Close | 4.66 | Low | 4.33 | High | 4.79 | Mkt Cap | 349.42M |
| Vol | 852.56K | Avg Vol | 892.75K | EPS | -1.12 | P/E | N/A | Forward P/E | -2.24 |
| Beta | N/A | Short Ratio | 6.55 | Inst. Own | 91.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 5.15 | 200-d Avg | 7.13 | 1yr Est | 22.29 |
| Income Statement | |||
| Operating Expenses | 22.33M | ||
| Research and Development Expense | 15.70M | ||
| Selling, General and Administrative Expense | 6.63M | ||
| Operating Income | -22.33M | ||
| Interest Expense | 17.00K | ||
| Net Income | -20.20M | ||
| Net Income Common Stock | -20.20M | ||
| Net Income Common Stock (USD) | -20.20M | ||
| Consolidated Income | -20.20M | ||
| Earnings per Basic Share | -0.25 | ||
| Earnings per Basic Share (USD) | -0.25 | ||
| Earnings per Diluted Share | -0.25 | ||
| Earning Before Interest & Taxes (EBIT) | -20.18M | ||
| Earning Before Interest & Taxes (USD) | -20.18M | ||
| Weighted Average Shares | 81.18M | ||
| Weighted Average Shares Diluted | 81.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 75.02M | ||
| Cash and Equivalents (USD) | 75.02M | ||
| Investments | 159.18M | ||
| Investments Current | 121.28M | ||
| Investments Non-Current | 37.90M | ||
| Current Assets | 200.86M | ||
| Property, Plant & Equipment Net | 8.35M | ||
| Total Assets | 250.36M | ||
| Debt Current | 2.70M | ||
| Total Debt | 7.37M | ||
| Current Liabilities | 14.19M | ||
| Debt Non-Current | 4.67M | ||
| Total Liabilities | 18.86M | ||
| Accumulated Retained Earnings (Deficit) | -400.33M | ||
| Accumulated Other Comprehensive Income | -142.00K | ||
| Shareholders Equity | 231.50M | ||
| Shareholders Equity (USD) | 231.50M | ||
| Assets Non-Current | 49.49M | ||
| Total Debt (USD) | 7.37M | ||
| Liabilities Non-Current | 4.67M | ||
| Trade and Non-Trade Payables | 3.34M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 546.00K | ||
| Net Cash Flow from Financing | 2.45M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.77M | ||
| Capital Expenditure | -35.00K | ||
| Issuance (Purchase) of Equity Shares | 2.57M | ||
| Issuance (Repayment) of Debt Securities | -121.00K | ||
| Net Cash Flow from Investing | 27.46M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 27.50M | ||
| Net Cash Flow from Operations | -21.14M | ||
| Share Based Compensation | 2.76M | ||